Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status:
Completed
Trial end date:
2015-04-08
Target enrollment:
Participant gender:
Summary
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and
placebo, as measured by the number of binge days (defined as days during which at least 1
binge episode occurs) per week as assessed by clinical interview based on subject diary and
Clinical Global Impression - Severity (CGI-S) scores for patients who responded to SPD489 by
the end of the Open-label Treatment Phase.